Open AccessErratum. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care 2016;39:139–148
Author(s) -
Tomoya Mita,
Naoto Katakami,
Hidenori Yoshii,
Tomio Onuma,
Hideaki Kaneto,
Takeshi Osonoi,
Toshihiko Shiraiwa,
Keisuke Kosugi,
Yutaka Umayahara,
Tsunehiko Yamamoto,
Hiroki Yokoyama,
Nobuichi Kuribayashi,
Hideaki Jinnouchi,
Masahiko Gosho,
Iichiro Shimomura,
Hirotaka Watada
Publication year - 2017
Publication title -
diabetes care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.636
H-Index - 363
eISSN - 1935-5548
pISSN - 0149-5992
DOI - 10.2337/dc17-er06b
Subject(s) - alogliptin , medicine , dipeptidyl peptidase 4 , diabetes mellitus , type 2 diabetes , dipeptidyl peptidase 4 inhibitor , endocrinology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom